HomeCompareBIOGF vs EQR

BIOGF vs EQR: Dividend Comparison 2026

BIOGF yields 303.03% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOGF wins by $1619.95M in total portfolio value
10 years
BIOGF
BIOGF
● Live price
303.03%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1619.99M
Annual income
$982,313,976.38
Full BIOGF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — BIOGF vs EQR

📍 BIOGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOGFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOGF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOGF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOGF
Annual income on $10K today (after 15% tax)
$25,757.58/yr
After 10yr DRIP, annual income (after tax)
$834,966,879.92/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, BIOGF beats the other by $834,962,225.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOGF + EQR for your $10,000?

BIOGF: 50%EQR: 50%
100% EQR50/50100% BIOGF
Portfolio after 10yr
$810.02M
Annual income
$491,159,725.99/yr
Blended yield
60.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

BIOGF
No analyst data
Altman Z
-7.1
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOGF buys
0
EQR buys
0
No recent congressional trades found for BIOGF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOGFEQR
Forward yield303.03%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1619.99M$47.8K
Annual income after 10y$982,313,976.38$5,475.61
Total dividends collected$1556.25M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: BIOGF vs EQR ($10,000, DRIP)

YearBIOGF PortfolioBIOGF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$41,003$30,303.03$11,380$679.82+$29.6KBIOGF
2$159,996$116,123.00$13,014$837.25+$147.0KBIOGF
3$594,671$423,475.49$14,961$1,036.20+$579.7KBIOGF
4$2,107,296$1,470,997.14$17,297$1,289.22+$2.09MBIOGF
5$7,126,460$4,871,653.73$20,121$1,613.15+$7.11MBIOGF
6$23,022,487$15,397,174.28$23,561$2,030.84+$23.00MBIOGF
7$71,121,500$46,487,438.99$27,783$2,573.54+$71.09MBIOGF
8$210,314,839$134,214,834.84$33,013$3,284.39+$210.28MBIOGF
9$595,961,579$370,924,701.05$39,547$4,223.51+$595.92MBIOGF
10$1,619,992,866$982,313,976.38$47,791$5,475.61+$1619.95MBIOGF

BIOGF vs EQR: Complete Analysis 2026

BIOGFStock

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Full BIOGF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this BIOGF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOGF vs SCHDBIOGF vs JEPIBIOGF vs OBIOGF vs KOBIOGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.